Co-activation of epidermal growth factor receptor and c-MET defines a distinct subset of lung adenocarcinomas.
暂无分享,去创建一个
[1] S. Ishikawa,et al. Molecular Predictors of Sensitivity to the MET Inhibitor PHA665752 in Lung Carcinoma Cells , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[2] M. Nikiforova,et al. Micropapillary lung adenocarcinoma: EGFR, K-ras, and BRAF mutational profile. , 2009, American journal of clinical pathology.
[3] S. Agarwal,et al. Association of constitutively activated hepatocyte growth factor receptor (Met) with resistance to a dual EGFR/Her2 inhibitor in non-small-cell lung cancer cells , 2009, British Journal of Cancer.
[4] Y. Ishikawa,et al. Correlation between morphology and EGFR mutations in lung adenocarcinomas Significance of the micropapillary pattern and the hobnail cell type. , 2009, Lung cancer.
[5] Igor Jurisica,et al. Gene expression–based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study , 2008, Nature Medicine.
[6] W. Gerald,et al. Lung Adenocarcinoma: Modification of the 2004 WHO Mixed Subtype to Include the Major Histologic Subtype Suggests Correlations Between Papillary and Micropapillary Adenocarcinoma Subtypes, EGFR Mutations and Gene Expression Analysis , 2008, The American journal of surgical pathology.
[7] Steven P Gygi,et al. Signaling networks assembled by oncogenic EGFR and c-Met , 2008, Proceedings of the National Academy of Sciences.
[8] E. Rosen,et al. Transcription-Dependent Epidermal Growth Factor Receptor Activation by Hepatocyte Growth Factor , 2008, Molecular Cancer Research.
[9] Y. Yatabe,et al. Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer , 2007, Cancer science.
[10] F. Schmitt,et al. P-cadherin expression in breast cancer: a review , 2007, Breast Cancer Research.
[11] S. Ishikawa,et al. Constitutive activation of c‐Met is correlated with c‐Met overexpression and dependent on cell–matrix adhesion in lung adenocarcinoma cell lines , 2007, Cancer science.
[12] D. Nie,et al. Cyclooxygenases, prostanoids, and tumor progression , 2007, Cancer and Metastasis Reviews.
[13] J. Siegfried,et al. Signaling Pathways Involved in Cyclooxygenase-2 Induction by Hepatocyte Growth Factor in Non–Small-Cell Lung Cancer , 2007, Molecular Pharmacology.
[14] D. Sheppard,et al. Integrin β6 Mediates Phospholipid and Collectin Homeostasis by Activation of Latent TGF-β1 , 2007 .
[15] Benjamin G. Bitler,et al. Transforming Growth Factor α–Dependent Cancer Progression Is Modulated by Muc1 , 2007 .
[16] Y. Miyagi,et al. Distinctive evaluation of nonmucinous and mucinous subtypes of bronchioloalveolar carcinomas in EGFR and K-ras gene-mutation analyses for Japanese lung adenocarcinomas: confirmation of the correlations with histologic subtypes and gene mutations. , 2007, American journal of clinical pathology.
[17] Yusuke Nakamura,et al. c‐Met activation in lung adenocarcinoma tissues: An immunohistochemical analysis , 2007, Cancer science.
[18] Joon-Oh Park,et al. MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling , 2007, Science.
[19] Y. Yatabe,et al. Epidermal growth factor receptor mutations in lung cancers , 2007, Pathology international.
[20] S. Ishikawa,et al. Hypoxia increases the motility of lung adenocarcinoma cell line A549 via activation of the epidermal growth factor receptor pathway , 2007, Cancer science.
[21] W. Pao,et al. Update on Epidermal Growth Factor Receptor Mutations in Non–Small Cell Lung Cancer , 2006, Clinical Cancer Research.
[22] S. Ishikawa,et al. Molecular karyotyping of human hepatocellular carcinoma using single-nucleotide polymorphism arrays , 2006, Oncogene.
[23] A. Ochiai,et al. Comparison of the immunophenotypes of signet‐ring cell carcinoma, solid adenocarcinoma with mucin production, and mucinous bronchioloalveolar carcinoma of the lung characterized by the presence of cytoplasmic mucin , 2006, The Journal of pathology.
[24] Takayuki Kosaka,et al. Expression profile-defined classification of lung adenocarcinoma shows close relationship with underlying major genetic changes and clinicopathologic behaviors. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] A. Jemal,et al. Cancer Statistics, 2006 , 2006, CA: a cancer journal for clinicians.
[26] J. Minna,et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. , 2006, Journal of the National Cancer Institute.
[27] T. Shibata,et al. Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] Hiroyuki Aburatani,et al. Allelic dosage analysis with genotyping microarrays. , 2005, Biochemical and biophysical research communications.
[29] D. Nunes,et al. Suppression of MUC1 synthesis downregulates expression of the epidermal growth factor receptor , 2005, Cancer biology & therapy.
[30] Y. Ishikawa,et al. Pulmonary Adenocarcinomas With Enteric Differentiation: Histologic and Immunohistochemical Characteristics Compared With Metastatic Colorectal Cancers and Usual Pulmonary Adenocarcinomas , 2005, The American journal of surgical pathology.
[31] K. Taniuchi,et al. Overexpressed P-cadherin/CDH3 promotes motility of pancreatic cancer cells by interacting with p120ctn and activating rho-family GTPases. , 2005, Cancer research.
[32] G. Rossi,et al. TTF-1, cytokeratin 7, 34betaE12, and CD56/NCAM immunostaining in the subclassification of large cell carcinomas of the lung. , 2004, American journal of clinical pathology.
[33] Patricia L. Harris,et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.
[34] R. Haba,et al. The tumour–stromal interaction between intratumoral c-Met and stromal hepatocyte growth factor associated with tumour growth and prognosis in non-small-cell lung cancer patients , 2004, British Journal of Cancer.
[35] J. Yokota,et al. Molecular footprints of human lung cancer progression , 2004, Cancer science.
[36] S. Hirohashi,et al. Cell adhesion system and human cancer morphogenesis , 2003, Cancer science.
[37] Miyuki Saito,et al. Frequent co-localization of Cox-2 and laminin-5 gamma2 chain at the invasive front of early-stage lung adenocarcinomas. , 2002, The American journal of pathology.
[38] Jungsil Ro,et al. Micropapillary Component in Lung Adenocarcinoma: A Distinctive Histologic Feature With Possible Prognostic Significance , 2002, The American journal of surgical pathology.
[39] M. Omary,et al. 'Hard' and 'soft' principles defining the structure, function and regulation of keratin intermediate filaments. , 2002, Current opinion in cell biology.
[40] D. Botstein,et al. Diversity of gene expression in adenocarcinoma of the lung , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[41] E. Lander,et al. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[42] S. Batra,et al. Structural organization and classification of the human mucin genes. , 2001, Frontiers in bioscience : a journal and virtual library.
[43] R. Tsuchiya,et al. Prognosis and survival after resection for bronchogenic carcinoma based on the 1997 TNM-staging classification: the Japanese experience. , 2001, The Annals of thoracic surgery.
[44] J. Coebergh,et al. Trends in incidence and prognosis of the histological subtypes of lung cancer in North America, Australia, New Zealand and Europe. , 2001, Lung cancer.
[45] H Aburatani,et al. Direct comparison of GeneChip and SAGE on the quantitative accuracy in transcript profiling analysis. , 2000, Genomics.
[46] J. Jankowski,et al. Aberrant P‐cadherin expression is a feature of clonal expansion in the gastrointestinal tract associated with repair and neoplasia , 2000, The Journal of pathology.
[47] M. Tsao,et al. Differential expression of Met/hepatocyte growth factor receptor in subtypes of non-small cell lung cancers. , 1998, Lung cancer.
[48] T. Yamamoto,et al. Hepatocyte growth factor and c-Met/hepatocyte growth factor receptor in pulmonary adenocarcinomas: an evaluation of their expression as prognostic markers. , 1996, Oncology.
[49] K. Tryggvason,et al. Laminin-5 is a marker of invading cancer cells in some human carcinomas and is coexpressed with the receptor for urokinase plasminogen activator in budding cancer cells in colon adenocarcinomas. , 1995, Cancer research.
[50] Benjamin G. Bitler,et al. Transforming growth factor alpha dependent cancer progression is modulated by Muc1. , 2007, Cancer research.
[51] D. Sheppard,et al. Integrin beta6 mediates phospholipid and collectin homeostasis by activation of latent TGF-beta1. , 2007, American journal of respiratory cell and molecular biology.
[52] 三好 立,et al. Early-stage lung adenocarcinomas with a micropapillary pattern, a distinct pathologic marker for a significantly poor prognosis , 2003 .